Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China
Open Access
- 12 May 2021
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000), 000
- https://doi.org/10.14218/jcth.2020.00097
Abstract
Hepatitis C virus (HCV) genotype (GT)3 infection is associated with a more rapid hepatic disease progression than the other genotypes. Hence, early HCV clearance slows down the disease progression and is important for improving prognosis in GT3-infected patients. Nevertheless, compared with other genotypes, GT3 is difficult-to-treat with direct-acting antivirals, especially in the presence of cirrhosis. Current guidelines recommend several regimens which have been proven to be effective in GT3-infected patients from the Western world (North America, Europe, and Oceania). In China, GT3 infection comprises 8.7–11.7% of the 10 million patients infected with HCV and has strikingly different characteristics from that in Western countries. Unlike the Western countries, where GT3a is the predominant subtype, GT3a and 3b each affect roughly half of Chinese GT3-infected patients, with 94–96% of the GT3b-infected patients carrying A30K+L31M double NS5A resistance-associated substitutions. Phase 3 clinical trials including GT3b-infected patients have suggested that GT3b infection is difficult to cure, making the regimen choice for GT3b-infected patients an urgent clinical gap to be filled. This review includes discussions on the epidemiology of HCV GT3 in China, recommendations from guidelines, and clinical data from both Western countries and China. The aim is to provide knowledge that will elucidate the challenges in treating Chinese GT3-infected patients and propose potential solutions and future research directions.Keywords
This publication has 49 references indexed in Scilit:
- Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6Virology Journal, 2015
- Sorting out cirrhosis: mechanisms of non‐response to hepatitis C therapyLiver International, 2015
- All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyJournal of Hepatology, 2015
- Injecting drug use: A vector for the introduction of new hepatitis C virus genotypesWorld Journal of Gastroenterology, 2015
- Global distribution and prevalence of hepatitis C virus genotypesJournal of Hepatology, 2014
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3The New England Journal of Medicine, 2014
- HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCVJournal of Hepatology, 2014
- Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3Journal of Viral Hepatitis, 2013
- Prevalence and risk factors of hepatitis C and B virus infections in hemodialysis patients and their spouses: A multicenter study in Beijing, ChinaJournal of Medical Virology, 2013
- The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidenceAddiction, 2011